Dexamethasone lowers mortality, ventilation use in ARDS
22 Feb 2021
bởiStephen Padilla
Treatment with intravenous (IV) dexamethasone for 10 days significantly reduces duration of mechanical ventilation at 28 days and 60-day mortality in patients with established moderate-to-severe acute respiratory disease syndrome (ARDS) compared with no dexamethasone, results of the DEXA-ARDS trial have shown.
Dexamethasone lowers mortality, ventilation use in ARDS
22 Feb 2021